JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB273860

Human HNRNPD knockout U-2 OS cell line

Be the first to review this product! Submit a review

|

(0 Publication)

HNRNPD KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

ARE binding protein AUFI type A, AU-rich element RNA-binding protein 1, AUF, AUF1, AUF1A, HNRPD_HUMAN, Heterogeneous nuclear ribonucleoprotein D0, P37, hnRNP D, hnRNP D0

4 Images
Western blot - Human HNRNPD knockout U-2 OS cell line (AB273860)
  • WB

Lab

Western blot - Human HNRNPD knockout U-2 OS cell line (AB273860)

False colour image of Western blot : Anti-hnRNP D/AUF1 antibody [EPR24001-12] staining at 1/1000 dilution shown in green; loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) staining at 1/20000 dilution shown in red. In Western blot ab259895 was shown to bind specifically to hnRNP D/AUF1. A band was observed at 40 kDa in wild-type U-2 OS cell lysates with no signal observed at this size in HNRNPD knockout cell line ab273860 (knockout cell lysate ab273814). To generate this image wild-type and HNRNPD knockout U-2 OS cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-hnRNP D/AUF1 antibody [EPR24001-12] (<a href='/en-us/products/primary-antibodies/hnrnp-d-auf1-antibody-epr24001-12-ab259895'>ab259895</a>) at 1/1000 dilution

Lane 1:

Wild-type U-2 OS cell lysate at 20 µg

Lane 2:

HNRNPD knockout U-2 OS cell lysate at 20 µg

Lane 2:

Western blot - Human HNRNPD knockout U-2 OS cell line (ab273860)

Predicted band size: 38 kDa

Observed band size: 40 kDa

false

Western blot - Human HNRNPD knockout U-2 OS cell line (AB273860)
  • WB

Lab

Western blot - Human HNRNPD knockout U-2 OS cell line (AB273860)

Lanes 1 - 4 : Merged signal (red and green). Green - ab50692 observed at 40 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.

ab50692 was shown to react with hnRNP D/AUF1 in wild-type U-2 OS cells in western blot with loss of signal observed in HNRNPD knockout cell line ab273860 (knockout cell lysate ab273814). Wild-type and HNRNPD knockout U-2 OS cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab50692 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at 1.25 μg/ml and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Anti-hnRNP D/AUF1 antibody (<a href='/en-us/products/unavailable/hnrnp-dauf1-antibody-ab50692'>ab50692</a>) at 1.25 µg/mL

Lane 1:

Wild-type U-2 OS (Human bone osteosarcoma epithelial cell line) whole cell lysate at 20 µg

Lane 2:

HNRNPD knockout U-2 OS (Human bone osteosarcoma epithelial cell line) whole cell lysate at 20 µg

Lane 2:

Western blot - Human HNRNPD knockout U-2 OS cell line (ab273860)

Lane 3:

Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate at 20 µg

Lane 4:

HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate at 20 µg

false

Next Generation Sequencing - Human HNRNPD knockout U-2 OS cell line (AB273860)
  • NGS

Supplier Data

Next Generation Sequencing - Human HNRNPD knockout U-2 OS cell line (AB273860)

5 bp deletion after Pro83 of the WT protein

Next Generation Sequencing - Human HNRNPD knockout U-2 OS cell line (AB273860)
  • NGS

Supplier Data

Next Generation Sequencing - Human HNRNPD knockout U-2 OS cell line (AB273860)

Knockout achieved by CRISPR/Cas9; X = 5 bp deletion; Frameshift : 100%

Key facts

Cell type

U-2 OS

Species or organism

Human

Tissue

Bone

Form

Liquid

form

Knockout validation

Next Generation Sequencing,Western blot

Mutation description

Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%

Disease

Osteosarcoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab273860-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab273860 Human HNRNPD knockout U-2 OS cell line", "number":"AB273860-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab263976 Human wild-type U-2 OS cell line", "number":"AB273860-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab273860-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab273860 Human HNRNPD knockout U-2 OS cell line", "number":"AB273860-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
HNRNPD
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

McCoY5a + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The hnRNP D/AUF1 protein also known as heterogeneous nuclear ribonucleoprotein D has a molecular mass of approximately 37-40 kDa. It plays a significant role in the cellular machinery by binding to RNA molecules mainly impacting mRNA stability and turnover. The protein is expressed ubiquitously in various tissues throughout the body indicating its importance in numerous cellular functions. It is one of the hnRNP family members involved in the post-transcriptional regulation of gene expression.
Biological function summary

HnRNP D/AUF1 regulates the degradation of mRNA by binding to AU-rich elements (AREs) found in the 3' untranslated region of many genes. It is an integral part of RNA-protein complexes that are important for controlling the half-life of mRNAs. Besides mRNA decay hnRNP D/AUF1 participates in other processes like mRNA splicing and transport. Its interactions within the ribonucleoprotein complexes highlight its versatile role in RNA metabolism.

Pathways

HnRNP D/AUF1 operates within important biological processes such as the mRNA decay pathway and the stress response pathway. It interacts closely with other proteins involved in mRNA decay such as tristetraprolin and members of the poly-A binding protein family. hnRNP D/AUF1 influences the decay rate of different transcripts contributing to cellular responses to environmental stimuli and maintaining homeostasis.

HnRNP D/AUF1 links to inflammatory conditions and some types of cancer. Altered expression levels of AUF1 have been associated with chronic inflammation where its role in mRNA stability impacts the expression of cytokines. In cancer dysregulation of AUF1 can lead to incorrect mRNA turnover of tumor suppressors or oncogenes linking it to proteins like p53 in the context of tumorigenesis. These associations make hnRNP D/AUF1 a potential target for therapeutic interventions in related diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com